Page 5 - Cardio_11_2021
P. 5

For patients living with heart failure,

                                                                       Time is essential.                 1,2


                                                                       So is                                   3,4






                                                                                 *as a second-line therapy, replacing ACE inhibitors or ARB. 5





       Give patients QoL and longer life expectancy with VYMADA                                ®6,7


       Compared to an ACEi, patients on Vymada
               -  show an improved quality of life (based on overall KCCQ score) 7
               -  have a reduced risk of hospitalisations for heart failure 8

               -  have a projected increased life expectancy 6

                                                                                     ®
                                VYMADA ®                               Treatment with VYMADA  can increase remaining
                     ACEi                                                  life expectancy up to 28% vs ACEi  6
           Cardiac function   and QoL  early and sustained improvements
                With VYMADA ® , patients reported
                  in how they feel vs ACEi 7
                                       Hospitalisations                  Add up to 2 years
                                                                       of life for your patients 6
           DIAGNOSIS
                    1 YEAR      2 YEARS    3 YEARS     4 YEARS   5 YEARS    6 YEARS     7 YEARS
                                             Disease progression
                                                               Adapted from Mesquita et al 1  and Gheorghiade et al  2
       In PARADIGM-HF, VYMADA reduces HF hospitalisations and CV death       %    reduction in CV
                                                                 8
                                                                         20RRR    death or first HF
               40                                                         p<0.0001  hospitalisation
                                                                          Primary
                                                                          end point
           Cumulative probability of  HF hospitalisation or CV death (%)  30  NNT=21
                                                                          27 month NNT
               20
                                                                         For ARNI therapy
                                                                          incremental
                                                                          to ACEI therapy
               10
                                                                          VYMADA
               0
                                                                          Enalapril ®
                 0   180    360     540    720    900    1080   1260
                         Time since randomisation (days)                  Adapted from McMurray et al 8
       PARADIGM-HF trial was stopped early, after a median follow-up of 27 months, because the boundary
       for benefit with VYMADA  had been crossed.  8
                               ®
       QoL = Quality of Life; KCCQ-OS = Kansas City Cardiomyopathy Questionnaire Overall Summary Score; ACEi = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blockers;
       CV = cardiovascular; HF = heart failure
       For any Vymada product related enquiries, please contact the Novartis Customer Contact Centre on 0861 929 929
                      ®
       REFERENCES: 1. Mesquita ET, Jorge AJL, Rabelo LM, Souza CV. Understanding hospitalization in patients with heart failure. Int J Cardiovasc Sci 2017;30(1):81-90. 2. Gheorghiade M,
       Luca LD, Fonarow GC, et al. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol. 2005;96(6A): 1 IG-17G. 3. Ponikowski P, Voors AA, Anker SD, et
       al, for the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). 2016 ESC Guidelines for the diagnosis and treatment
       of acute and chronic heart failure. Eur Heart J. 2016;37:2129-2200. 4. Hitzeroth J, Mpe M, Klug E, et al, on behalf of the Heart Failure Society of South Africa. 2020 Heart Failure Society
       of South Africa perspective on the 2016 European Society of Cardiology Chronic Heart Failure Guidelines. S Afr Med J 2020;110(9b):938-951. https://doi.org/10.7196/SAMJ.2020.
       v110i8.14681. 5. Vymada ®  Package insert, Novartis South Africa (Pty) Ltd; September 2017. 6. Claggett B, Packer M, McMurray JJV, et al. Estimating the Long-Term Treatment Benefits of
       Sacubitril-Valsartan. N Engl J Med 2015;373(23): 2289-2290. 7. Khariton Y, Fonarow GC, Arnold SV, et al. Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes
       in Heart Failure With Reduced Ejection Fraction. JACC Heart Failure 2019;7(11):933-941. 8. McMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril
       in heart failure. N Engl J Med. 2014;371(11):993-1004. 9. Desai AS, Claggett BL, Packer M, et al. Influence of sacubitril/valsartan (LCZ696) on 30-day readmission after heart failure
       hospitalization. J Am Coll Cardiol. 2016;68(3):241-248.
       SCHEDULING STATUS: S3 VYMADA ®  50 mg film-coated tablets Reg. No. 50/7.6/1019, each film-coated tablet contains 24 mg sacubitril and 26 mg valsartan. VYMADA ®  100 mg
       film-coated tablets Reg. No. 50/7.6/1020, each film-coated tablet contains 49 mg sacubitril and 51 mg valsartan. VYMADA ®  200 mg film-coated tablets Reg. No. 50/7.6/1021, each
       film-coated tablet contains 97 mg sacubitril and 103 mg valsartan                     Scan QR code
       Note: Before prescribing, consult full prescribing information.                      for full professional
                                                                                              information
       Novartis South Africa (Pty) Ltd. Magwa Crescent West, Waterfall City, Jukskei View, 2090. Tel +27 11 3476000. Company Reg No: 1946/020671/07
       For any product related enquiries, please contact the Novartis Customer Contact Centre on 0861 929 929
       ZA2111159779  Exp. 15/11/2023



                                                                                                             2021/11/18   09:07
   00243_VYM_Outpatient A4 AD.indd   1
   00243_VYM_Outpatient A4 AD.indd   1                                                                       2021/11/18   09:07
   1   2   3   4   5   6   7   8   9   10